Morgan Stanley downgrades Novo Nordisk stock rating on growth concerns

Morgan Stanley downgraded Novo Nordisk to Underweight from Equalweight and set a $40 price target, below the $44.01 trading price, citing slowing growth, rising GLP-1 competition and semaglutide patent-expiry risk. The bank forecasts only 2%-3% revenue and EBIT growth in 2027 and 4% revenue/EBIT CAGR through 2030, versus 4% revenue and 7% EBIT CAGR for European pharma, while semaglutide is projected to represent 75% of 2026 sales. Although Novo delivered Q2 2026 adjusted EPS of $0.9527 versus $0.7815 consensus and $12.1B revenue versus $10.94B expected, prescription trends indicate share losses to Eli Lilly's Zepbound and Mounjaro, tempering the outlook.

Analysis

The relevant investment question is not whether GLP-1 demand persists, but whether NVO can retain enough of the profit pool to justify a premium pharma multiple. A sustained share shift toward LLY would pressure NVO through lower volume, greater rebate spending, and weaker utilization of its manufacturing base; the latter creates disproportionate EBIT downside even if category sales continue growing. LLY gains incremental payer leverage as its share rises, supporting formulary access and making share losses potentially self-reinforcing over the next 1-3 months.

The market may be underestimating the importance of oral obesity execution. If NVO's prescription deceleration is confirmed in weekly U.S. data, expectations for the oral launch to broaden the funnel rather than cannibalize existing injectable demand will need to reset. China approval progress is strategically useful but unlikely to offset a U.S. mix and pricing deterioration near term, given reimbursement, localization, and launch-investment requirements; it should not be capitalized as a near-term earnings offset.

A short NVO thesis has limited attractiveness after the downgrade if valuation already reflects a low-growth outcome. The cleaner expression is relative: LLY's share gains can drive estimate revisions while NVO faces de-rating risk, but LLY's richer valuation makes the pair vulnerable to any category-wide reimbursement shock. Over 6-18 months, the larger risk to both is that payer controls and competing multi-agonists turn an apparent demand-constrained market into a price-competitive one, shifting value toward PBMs and insurers rather than drug manufacturers.

Key Decisions for Investors

• Initiate a 1-3 month market-neutral pair: long LLY / short NVO, sized beta-neutral. Use a 10-12% relative-performance target; exit if NVO U.S. prescription trends stabilize for four consecutive weekly reads or if LLY's next earnings call fails to raise obesity volume/revenue guidance.
• Do not add outright NVO short exposure solely on the broker action. Add only after a quarterly cut to obesity guidance, evidence of higher gross-to-net deductions, or a material U.S. share-loss datapoint; absent those, downside is vulnerable to China/oral-launch headlines and short covering.
• Monitor weekly GLP-1 prescription share and Medicare formulary developments through the next earnings cycle. A broad category volume slowdown or adverse reimbursement policy is a falsifier for the long LLY leg; hedge pair exposure with a modest IBB or XBI short only if biotech beta becomes the dominant risk.
• For existing LLY longs, protect the 6-18 month valuation risk with defined-risk put spreads around the next major reimbursement or competitor trial catalyst rather than reducing the position outright; the near-term share-gain setup remains favorable, but a pricing-led multiple compression can overwhelm earnings revisions.